Moleculin Biotech (MBRX) PT Raised to $18 at Oppenheimer
- Wall Street ends week positively; S&P 500, Dow hit record highs
- Bitcoin (BTC) Drops 3% as Turkey Bans Cryptocurrency Payments Citing Lack of Regulatory Supervision
- Morgan Stanley (MS) Archegos-Related Loss Appears to be $911M
- Dollar at 4-week low on retreating Treasury yields
- J&J (JNJ) Privately Asked Rival Covid-19 Vaccine Makers to Inspect Clotting Risks, AstraZeneca (AZN) Said Yes but Pfizer (PFE) and Moderna (MRNA) Declined - Report
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Oppenheimer analyst Kevin DeGeeter raised the price target on Moleculin Biotech (NASDAQ: MBRX) to $18.00 (from $12.00) while maintaining an Outperform rating.
The analyst commented, "Our investment thesis for shares on MBRX has been based primarily on: 1) differentiated cardiovascular safety profile of annamycin compared to other anthracyclines; and 2) intriguing in vivo data suggesting elevated annamycin concentrations in lung might provide promise in treating lung metastasis - a setting where other anthracyclines have limited activity. Raising PT to $18 from post-split adjusted $12 based on data released this week demonstrating impressive survival benefit in preclinical model of osteosarcoma lung mets. Our new 2021 and 2022 EPS estimates are ($0.96) and ($1.06), respectively, reflecting 1-for-6 reserve stock split partially offset by dilution from recent $68M equity financing. We now believe MBRX may have sufficient cash balance to fund operations through to profitability."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bayerische Motoren Werke AG (BMW:GR) (BMWYY) PT Raised to EUR108 at Goldman Sachs
- Hella GmbH & Co KGaA (HLE:GR) (HLLGY) PT Lowered to EUR42 at Morgan Stanley
- Seven Group Holdings Limited (SVW:AU) (SVNWF) PT Raised to AUD27.50 at Credit Suisse
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!